Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT07359417
MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma (ESCALATE)
Improving Outcome of Patients With Squamous Cell ESophageal CArcinoma by Dose escaLATion Using High-prEcision Mr-guided Radiotherapy (ESCALATE): a Phase 1 Dose Finding Trial
Sponsor: UMC Utrecht
Interventions
Radiation: MRI guided radiotherapy
Updated 1 time since 2026 Last updated: Jan 13, 2026 Started: May 30, 2025 Primary completion: May 1, 2028 Completion: May 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Esophageal Cancer, Squamous Cell and Esophageal Squamous Cell Carcinoma (ESCC) and is currently actively recruiting participants. UMC Utrecht leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- UMC Utrecht
Data source: UMC Utrecht
For direct contact, visit the study record on ClinicalTrials.gov .